James Abbruzzese, MD

Professor of Medicine
D. C. I. Professor of Medical Oncology
Chief, Division of Medical Oncology
Member of the Duke Cancer Institute
Campus mail 440 Mudd Building, Box 3406, Durham, NC 27710
Email address james.abbruzzese@duke.edu

My research interests include the clinical study and treatment of pancreatic cancer.

In Their Words

Education and Training

  • Resident, Internal Medicine, Johns Hopkins University School of Medicine, 1979 - 1981
  • Intern, Internal Medicine, Johns Hopkins University School of Medicine, 1978 - 1979
  • M.D., University of Chicago, 1978

Publications

Ettinger, D. S., J. L. Abbruzzese, R. A. Gams, C. D. Jacobs, M. S. Kies, J. Orner, D. Raben, et al. “NCCN practice guidelines for occult primary tumors.” Oncology 12, no. 11 A (1998): 226–309.

Scholars@Duke

Breslin, T. M., N. A. Janjan, J. E. Lee, P. W. Pisters, R. A. Wolff, J. L. Abbruzzese, and D. B. Evans. “Neoadjuvant chemoradiation for adenocarcinoma of the pancreas.” Frontiers in Bioscience : A Journal and Virtual Library 3 (1998): E193–203.

Scholars@Duke

Wang, M., J. L. Abbruzzese, H. Friess, W. N. Hittelman, D. B. Evans, M. C. Abbruzzese, P. Chiao, and D. Li. “DNA adducts in human pancreatic tissues and their potential role in carcinogenesis.” Cancer Res 58, no. 1 (January 1, 1998): 38–41.

PMID
9426054
Scholars@Duke

Miller, A. R., E. K. Robinson, J. E. Lee, P. W. Pisters, P. J. Chiao, R. L. Lenzi, J. L. Abbruzzese, and D. B. Evans. “Neoadjuvant chemoradiation for adenocarcinoma of the pancreas.” Surg Oncol Clin N Am 7, no. 1 (January 1998): 183–97.

PMID
9443995
Scholars@Duke

Pazdur, R., D. C. Medgyesy, R. J. Winn, S. R. Dakhil, D. F. Moore, A. Scalzo, P. M. Hoff, S. G. Arbuck, and J. L. Abbruzzese. “Phase II trial of 9-aminocamptothecin (NSC 603071) administered as a 120-hr continuous infusion weekly for three weeks in metastatic colorectal carcinoma.” Invest New Drugs 16, no. 4 (1998): 341–46. https://doi.org/10.1023/a:1006248700232.

PMID
10426669
Full Text

Abbruzzese, J. L. “The Michael/Moore Article Reviewed.” Oncology 11, no. 11 (December 1, 1997): 1622–25.

Scholars@Duke

Pazdur, R., C. Meyers, E. Diaz-Canton, J. L. Abbruzzese, Y. Patt, W. Grove, and J. Ajani. “Phase II trial of intravenous CI-980 (NSC 370147) in patients with metastatic colorectal carcinoma. Model for prospective evaluation of neurotoxicity.” Am J Clin Oncol 20, no. 6 (December 1997): 573–76. https://doi.org/10.1097/00000421-199712000-00008.

PMID
9391543
Full Text

Mason, K. A., N. R. Hunter, M. Milas, J. L. Abbruzzese, and L. Milas. “Docetaxel enhances tumor radioresponse in vivo.” Clin Cancer Res 3, no. 12 Pt 1 (December 1997): 2431–38.

PMID
9815644
Scholars@Duke

NCCN practice guidelines for pancreatic cancer.” Oncology (Williston Park) 11, no. 11A (November 1997): 41–55.

PMID
9430178
Scholars@Duke

Ferrandina, G., B. Melichar, A. Loercher, C. F. Verschraegen, A. P. Kudelka, C. L. Edwards, G. Scambia, J. J. Kavanagh, J. L. Abbruzzese, and R. S. Freedman. “Growth inhibitory effects of sodium phenylacetate (NSC 3039) on ovarian carcinoma cells in vitro.” Cancer Res 57, no. 19 (October 1, 1997): 4309–15.

PMID
9331092
Scholars@Duke

Pages